FierceBiotech22h
Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
GlobalData on MSN2d
Selkirk Pharma introduces new service for rapid delivery of trial supplies
Through ClinFAST, Selkirk is focused on meeting critical clinical timelines. Selkirk Pharma CEO Colleen Dixon said: “In ...
EurekAlert!4d
Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AI
Insilico Medicine ( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today ...
ALS News Today4d
US trial of noninvasive ALS device gets green light to enroll patients
A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Boehringer Ingelheim Limited: Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...
Precigen: Successful Proof Of Platform, But Cash Worries Remain
Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...